PCM
VYGR icon

Penserra Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Penserra Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-870
Closed -$2K – 1565
2021
Q3 		$2K Buy
870
+10
+1% +$32 ﹤0.01% 1437
2021
Q2 		$3K Buy
860
+10
+1% +$45 ﹤0.01% 1328
2021
Q1 		$4K Sell
850
-10
-1% -$68 ﹤0.01% 1092
2020
Q4 		$6K Buy
860
+540
+169% +$5.19K ﹤0.01% 977
2020
Q3 		$3K Buy
+320
New +$3.76K ﹤0.01% 892

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penserra Capital Management's VYGR Position: Q4 2021 in Review

Penserra Capital Management sold out of Voyager Therapeutics (VYGR) in Q4 2021, closing a stake of 870 shares — an estimated $2K sold.

Penserra Capital Management first reported a position in VYGR in Q3 2020 and held it in 5 quarters. The position peaked at $6K in Q4 2020. 59 funds tracked by Wall St. Rank hold VYGR as of Q4 2021.

  • Penserra Capital Management reported no remaining Voyager Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 870 Voyager Therapeutics shares in Q4 2021, an estimated $2K.
  • Penserra Capital Management first reported a position in Voyager Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Voyager Therapeutics position peaked at $6K in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.